Study outcomes
SECONDARY
The primary outcome measure was the change in serum phosphorus levels from baseline values at 8 weeks. The secondary outcome measures were changes in serum phosphorus levels from baseline values at each time point; proportion of patients achieving the target serum phosphorus level (serum phosphorus level: 3.5–6.0 mg/dL); time when the target serum phosphorus level (serum phosphorus level: 3.5–6.0 mg/dL) was achieved; and changes in the concentrations of Ca × P product and serum corrected calcium levels at each time point.As exploratory endpoints, intact fibroblast growth factor 23 (FGF23) levels, c-terminal FGF23 levels, changes in intact parathyroid hormone (iPTH) levels from baseline, and changes in bone turnover markers (bone-specific alkaline phosphatase [BSAP], tartrate-resistant acid phosphatase [TRACP-5b], osteocalcin, and procollagen type I N propeptide [P1NP]) from baseline were evaluated.